Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

On-Demand e-Posters Display

157P - Surufatinib plus toripalimab in patients with advanced small cell lung cancer (SCLC) after failure of 1L systemic chemotherapy

Date

09 Dec 2021

Session

On-Demand e-Posters Display

Presenters

Ying Cheng

Citation

Annals of Oncology (2021) 32 (suppl_7): S1428-S1457. 10.1016/annonc/annonc787

Authors

Y. Cheng1, L. Shen2, X. Yu3, Z. Chen4, L. Song5, Y. Zhang6, C. Wu7, M. Lu8, H. Gao9, W. Chen10, M. Yang11, Y. Ma6, J. Zhou12, H. Shi12, P. Tan12, S. Fan12, W. Su12

Author affiliations

  • 1 Jilin Cancer Hospital, Chaoyang Borough, 130021 - Changchun/CN
  • 2 Peking University Cancer Hospital & Institute, Beijing/CN
  • 3 Fudan University Shanghai Cancer Center, Shanghai/CN
  • 4 The Second Hospital of Anhui Medical University, Heifei/CN
  • 5 The First Affiliated Hospital of Zhengzhou University, Zhengzhou/CN
  • 6 Harbin Medical University Cancer Hospital, Harbin/CN
  • 7 Jilin Province Cancer Hospital, Changchun/CN
  • 8 Peking University Cancer Hospital & Institute, 100000 - Beijing/CN
  • 9 Fudan university Shanghai cancer center, Shanghai/CN
  • 10 The second hospital of Anhui Medical University, Heifei/CN
  • 11 The first affiliated hospital of Zhengzhou university, Zhengzhou/CN
  • 12 HUTCHMED, Shanghai/CN
More

Abstract 157P

Background

Patients (pts) with advanced SCLC have a rapid relapse after 1L treatment, and only one approved agent (topotecan) for 2L treatment. Surufatinib (S, a small-molecule inhibitor of VEGFR1-3, FGFR1 and CSF-1R) plus toripalimab (T, an anti-PD-1 antibody) has exhibited encouraging efficacy in a neuroendocrine carcinoma cohort in a trial evaluating S + T in pts with selected solid tumors. Here, we report the safety and efficacy results in the SCLC cohort.

Methods

In this cohort of the multicenter, multi-cohort, single-arm phase 2 study (NCT04169672), adults (18-75) with advanced SCLC who had failed 1L systemic chemotherapy (platinum-based systemic chemotherapy) were eligible, and received 3-week cycles of S (250 mg orally, QD) plus T (240 mg IV, Q3W). The primary endpoint was objective response rate (ORR) per RECIST 1.1.

Results

At cutoff date (Aug 1, 2021), 20 pts (median age, 58 yrs; ECOG=1, 17 pts; PD-L1 CPS<1, 16 pts) were enrolled and received combination treatment. Median treatment duration of S and T was both 3 mo. Among pts with at least one post-baseline tumor assessment (evaluable pts, n=19), the confirmed ORR (2 PRs) was 10.5% (95%CI 1.3-33.14), DCR was 94.7% (95%CI 73.97-99.87). Median DoR was not reached. Median PFS (mPFS) was 2.96 mo (95%CI 2.79-4.11), and median OS (mOS) was 10.94 mo (95%CI 4.96-NR). In platinum-sensitive (n=8) and -resistant (n=12) subgroups (defined as pts with disease relapsed ≥90 days and <90 days, respectively, after platinum-based chemotherapy), the confirmed ORR (95%CI) in evaluable pts (n=8 and 11) were 0 and 18.2% (2.28-51.78), DCR (95%CI) were 87.5% (47.35-99.68) and 100% (71.51-100), respectively; mPFS (95%CI) were 3.4 mo (1.38-5.59) and 2.96 mo (2.69-4.11), and mOS (95%CI) were not reached (median duration of follow up, 11.10 mo) and 8.87 mo (4.34-NR), respectively. Nine (45%) pts reported TRAEs of grade ≥3, most commonly (≥2 pts) with hypertriglyceridemia and hypertension, both with 2 pts. No TRAEs led to treatment discontinuation or death.

Conclusions

S + T showed a promising anti-tumor activity and an acceptable toxicity for 2L treatment of SCLC. The combination of the two agents might be a novel 2L therapeutic option for SCLC.

Clinical trial identification

NCT04169672.

Editorial acknowledgement

We acknowledge Xia Yin (medical writer of HUTCHMED) for the abstract editing work.

Legal entity responsible for the study

HUTCHMED.

Funding

HUTCHMED.

Disclosure

J. Zhou, H. Shi, P. Tan, S. Fan, W. SuFinancial Interests, Personal, Full or part-time Employment: HUTCHMED. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.